Application of a series of monoclonal antibodies against human white cell differentiation antigens and the common acute lymphoblastic leukemia antigen in the characterization of leukemia cells
Holowiecki, J.; Stella Holowiecka, B.; Krawczyk Kulis, M.; Wiechnik, E.; Japa, J.; Jarczok, K.; Rudzka, E.; Duraj, M.
Archivum Immunologiae et Therapiae Experimentalis 32(1): 43-50
The specificity and the clinical usefulness of the hybridoma derived monoclonal antibodies raised against the differentiation antigens of granulocytes (VIM-D5, VIM-C6), monocytes (VIM-D2), B lymphocytes (VIB-C5, VIC-Y1), erythrocytes (VIE-G4) and CALLA [common acute lymphoblastic leukemia associated antigen] (VIL-A1) was studied in leukemic cells isolated from peripheral blood and bone marrow of 41 adults with acute leukemia by using indirect fluorescence method. The VIL-A1 positivity was observed in 4/9 of ALL [acute lymphoblastic leukemia] and in none of myeloid leukemia. It was accompanied in 3/4 of cases by VIB-C5 positivity and in 1 case by VIE-G4 positivity. It is important that 2 of 3 unclassifiable cases (PAS-) could be diagnosed as common ALL due to their VIL-A1 positivity. VIM-D5 like VIM-C6 reacted specifically with granulocytic cells only and gave positive results in 20/30 of acute myeloid leukemias [AML]. When classified according to the FAB scheme, the proportion of VIM-D5 + patients rose from M1 toward more mature subtypes, including M4/5. It was identified as AML 2/6 of unclassifiable-Mo leukemias. VIC-Y1 appeared to be helpful in characterization of B cell malignancies and of myelomonocytic leukemias. Evidently, the monoclonal antibodies of VI series are specific and allow a more precise definition of leukemia, thus helping in optimalization of treatment.